AstraZeneca PLC [NASDAQ: AZN] stock went on an upward path that rose over 1.15% on Wednesday, amounting to a one-week price increase of more than 2.58%. The company report on July 25, 2022 that ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to demonstrate a survival benefit in this population.
Application being evaluated under FDA Real-Time Oncology Review and Project Orbis.
Over the last 12 months, AZN stock rose by 17.46%. The one-year AstraZeneca PLC stock forecast points to a potential upside of 5.87. The average equity rating for AZN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $207.06 billion, with 3.10 billion shares outstanding and 2.99 billion shares in the current float. Compared to the average trading volume of 6.77M shares, AZN stock reached a trading volume of 4035253 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $71.70 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 14, 2022. The new note on the price target was released on February 11, 2022, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.50, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.99. The Price to Book ratio for the last quarter was 5.75, with the Price to Cash per share for the same quarter was set at 1.90. Price to Free Cash Flow for AZN in the course of the last twelve months was 114.21 with Quick ratio for the last quarter at 0.70.
AZN Stock Performance Analysis:
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.58. With this latest performance, AZN shares gained by 1.47% in over the last four-week period, additionally plugging by 16.66% over the last 6 months – not to mention a rise of 17.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 56.72, with the RSI for the last a single of trading hit 58.99, and the three-weeks RSI is set at 55.26 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 65.24, while it was recorded at 66.20 for the last single week of trading, and 61.92 for the last 200 days.
Insight into AstraZeneca PLC Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +7.57 and a Gross Margin at +60.90. AstraZeneca PLC’s Net Margin is presently recorded at +0.30.
Return on Total Capital for AZN is now 5.33, given the latest momentum, and Return on Invested Capital for the company is 0.22. Return on Equity for this stock inclined to 0.40, with Return on Assets sitting at 0.13. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 78.39. Additionally, AZN Total Debt to Total Capital is recorded at 43.94, with Total Debt to Total Assets ending up at 29.21. Long-Term Debt to Equity for the company is recorded at 73.57, with the Long-Term Debt to Total Capital now at 41.24.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $980 per employee. Receivables Turnover for the company is 5.18 with a Total Asset Turnover recorded at a value of 0.43.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.
AZN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 15.00%.
AstraZeneca PLC [AZN] Insider Position Details
There are presently around $34,797 million, or 17.80% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 94,229,869, which is approximately 4.885% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 46,691,035 shares of the stock with an approximate value of $3.15 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $3.13 billion in AZN stock with ownership of nearly -0.798% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 433 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 50,105,760 shares. Additionally, 403 investors decreased positions by around 37,024,312 shares, while 221 investors held positions by with 428,462,773 shares. The mentioned changes placed institutional holdings at 515,592,845 shares, according to the latest SEC report filing. AZN stock had 117 new institutional investments in for a total of 5,324,915 shares, while 78 institutional investors sold positions of 5,120,832 shares during the same period.